FDA approves vorasidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. News release. FDA, https://tinyurl.com/3jv48wa9 (6 August 2024).

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 2.2024 (25 July 2024).

Mellinghoff, I. K. et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N. Engl. J. Med. 389, 589–601 (2023).

CAS  PubMed  Google Scholar 

Buckner, J. C. et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N. Engl. J. Med. 374, 1344–1355 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

van den Bent, M. J. et al. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 22, 813–823 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Guillevin, R., Herpe, G., Verdier, M. & Guillevin, C. Low-grade gliomas: the challenges of imaging. Diagn. Interv. Imaging 95, 957–963 (2014).

Article  CAS  PubMed  Google Scholar 

National Institutes of Health. Basics of clinical research and trials. National Institutes of Health https://www.nih.gov/health-information/nih-clinical-research-trials-you/basics (accessed 10 August 2024).

Iwamoto, F. et al. CTNI-16. NRG-RTOG 9802 observation arm – long term result. Neuro-oncol 24 (Suppl. 7), vii73 (2022).

Article  Google Scholar 

Pertz, M. et al. Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up. J. Neurooncol. 164, 353–366 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Servier Pharmaceuticals’ vorasidenib receives FDA approval for glioma. MedCity News https://medcitynews.com/2024/08/brain-cancer-glioma-fda-approval-servier-pharmaceuticals-vorasidenib-voranigo/ (8 August 2024).